Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer's disease comorbidities?
Michael Davidson, Gabriela-Dumitrita Stanciu, Jonathan Rabinowitz, Ilinca Untu, Romeo-Petru Dobrin, Bogdan-Ionel Tamba
Dialogues Clin Neurosci March 19, 2025 DOI: 10.1080/19585969.2025.2480566 via PubMed Central
Summary
AI-generated from the abstractThis theoretical paper explores whether psychedelic-assisted therapy could address comorbidities often accompanying Alzheimer's disease, such as depression, anxiety, and social withdrawal. The authors argue that psychedelics may promote neuroplasticity, reduce inflammation, and facilitate psychological breakthroughs that improve quality of life. They suggest that combining psychedelic compounds with psychotherapy might offer a novel approach to managing behavioral and psychological symptoms of dementia. The paper calls for further research into safety, dosing, and ethical considerations for this vulnerable population, noting that current evidence is preliminary and based largely on extrapolation from studies in other conditions.
Study at a glance
| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Keywords | Psychedelics Mental health Neuroscience Alzheimer's disease Brain research |
| Citations | 2 |
| Key finding | Psychedelic-assisted therapy may offer a promising avenue for treating Alzheimer's disease comorbidities by promoting neuroplasticity and reducing inflammation, though evidence remains preliminary. |
Abstract
Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer's disease comorbidities?